| Thomas C Heineman |
Thomas C Heineman is currently the Chief Medical Officer at Oncolytics Biotech, Inc. He previously worked as the Senior Director-Clinical Research & Development at GSK Plc from 2006 to 2016. He also held the position of Associate Professor at Saint Louis University School of Medicine. From 2018 to 2020, he served as the Vice President & Head-Clinical Development at Halozyme Therapeutics, Inc. Additionally, he was the SVP & Head-Clinical Development at Denovo Biopharma LLC in 2020. From 2016 to 2020, he worked as the Vice President & Head-Clinical Development at Genocea Biosciences, Inc. Dr. Heineman holds graduate and doctorate degrees from The University of Chicago. |
| Kirk J. Look |
Kirk J. Look is currently the Chief Financial Officer at Oncolytics Biotech, Inc. and Oncolytics Biotech (U.S.), Inc. He previously worked as an Audit Manager & Senior Accountant at Ernst & Young Chile Ltda. and as a Manager-Audit & Assurance Services at Ernst & Young LLP (Canada). Mr. Look received his undergraduate degree from the University of Calgary and his graduate degree from Seton Hall University School of Law. |
| Wayne F. Pisano |
Mr. Wayne F. Pisano is an Independent Director at Altimmune, Inc., a Chairman at Oncolytics Biotech, Inc. and a President at Pirus Biological & Vaccine Consulting. He is on the Board of Directors at Altimmune, Inc., River Acquisition Corp. and Chattem, Inc. Mr. Pisano was previously employed as a Chairman by Provention Bio, Inc., a President, Chief Executive Officer & Director by VaxInnate Corp., an Independent Director by IMV, Inc., a President & Chief Executive Officer by Sanofi Pasteur, a Vice President by Novartis Pharmaceuticals Corp., and a Senior Vice President-Vaccines by Sanofi-Aventis SA. He also served on the board at Aeras Global TB Vaccine Foundation. He received his undergraduate degree from St. John Fisher College and an MBA from the University of Dayton. |
| Amy Levin |
Amy Levin is currently the Vice President-Clinical Operations at Oncolytics Biotech, Inc. Prior to her current position, she worked as the Senior Director-Clinical Operations at Puma Biotechnology, Inc. from 2011 to 2020. Before that, she was the Director-Clinical Program Leader at Janssen Oncology, Inc. from 2007 to 2011. Ms. Levin completed her undergraduate degree at The University of Texas at Austin. |
| Matthew C. Coffey |
Matthew C. Coffey has a career history that includes founding positions, current jobs, and education. He is the founder of Oncolytics Biotech, Inc., where he currently holds the title of President, CEO, COO & Director since 2016. He is also the founder of Oncolytics Biotech (U.S.), Inc., where he currently holds the title of Director. Dr. Coffey obtained a doctorate degree from the University of Calgary. |
| Angela Holtham |
Angela Holtham is an experienced professional with a background in finance and management. She is currently serving as an Independent Director at Oncolytics Biotech, Inc., and as a Director at both The Society of Management Accountants of Canada and Plexxus. Her former positions include Director roles at Ontario Financing Authority, Compute Canada, Inc., and Ontario Oncology Association. She also served as the Chief Financial Officer & Senior Vice President at Nabisco, Inc. and as the Chief Financial Officer & Vice President-Finance at The Hospital for Sick Children. Ms. Holtham holds an MBA from Rotman School of Management and an undergraduate degree from The University of Waterloo. |
| Deborah M. Brown |
Deborah M. Brown is an Independent Director at Oncolytics Biotech, Inc., Director at Life Sciences Ontario, Director & Managing Partner at Accelera Canada Ltd., and Director at Hamilton Burlington Spca. She was formerly the Chairman at Innovative Medicines Canada, Independent Director at Sernova Corp., Independent Director at Cardiol Therapeutics, Inc., Director at BIOTECanada, Executive Vice President-US Neuroimmunology at EMD Serono, Inc., and Manager-International Regulatory at Pasteur Mérieux Connaught. Brown holds an undergraduate degree from the University of Guelph and an MBA from the Richard Ivey School of Business. |
| Bernd Robert Seizinger |
Bernd Robert Seizinger is the founder and currently holds multiple positions. He is the Executive Chairman & Chief Executive Officer at CryptoMedix, Inc., which was founded in 2015. He is also currently an Independent Director at Aptose Biosciences, Inc., Oncolytics Biotech, Inc., Oxford BioTherapeutics Ltd., BioInvent International AB, Aprea Therapeutics AB, Nykode Therapeutics ASA, TriMod Therapeutics Ltd., Aprea Therapeutics, Inc., and Turbine Simulated Cell Technologies Ltd. Additionally, he is a Director at Karolinska Institutet. Dr. Seizinger has held former positions as the President & Chief Executive Officer at GPC Biotech AG from 1998 to 2009, an Independent Director at BioXell SpA from 2010 to 2012, the Director-Molecular Neuro-Oncology Laboratory at The General Hospital Corp. in 1992, a Director at Santhera Pharmaceuticals Holding AG from 2004 to 2011, a Non-Executive Director at Bionor Pharma ASA, the Chief Scientific Officer & Executive VP at Oscient Pharmaceuticals Corp., a Principal at Princeton University, the VP-Oncology Drug Discovery & Academic Alliances at Bristol-Myers Squibb Pharmaceutical Research Institute from 1992 to 1996, an Associate Professor-Neuroscience at Harvard Medical School in 1992, and a Member-Supervisory Board at Agennix AG. Dr. Seizinger's education includes a doctorate from Max-Planck-Institute for Molecular Genetics and Ludwig-Maximilians-Universität München. |
